ClinicalTrials.gg
CompletedNCT02617446Updated May 24, 2023Results posted

The Clinical Study of the Safety and Efficacy of Istaroxime in Treatment of Acute Decompensated Heart Failure

A Phase 2 interventional study of Placebo and Istaroxime in Acute Decompensated Heart Failure, sponsored by Windtree Therapeutics. Completed at 11 sites in 2 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-05-24.

Sponsored by Windtree Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 375 studies in Heart Failure with a site in China — 162 open to participants now, 182 under way, 18 of them phase 3. Heart Failure · China.

Enrollment
128th of 246
120 · median 127
Started
2015
with 10 others
Phase 2
22 of 375
6 open now
Registered
60th of 375
by date

Among the 375 studies in Heart Failure with a site in China, this one is the 128th largest by enrollment of the 246 interventional ones that give a count, is one of 11 that started in 2015, is one of 22 in phase 2, and was the 60th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

162 of the 375 studies in Heart Failure with a site in China are open now. Recruiting first, the newest first:

157 more — sign in →

All 162 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 375 studies in Heart Failure with a site in China, or all of them as a file.
02

Study summary

To assess the safety, tolerability and efficacy of two different doses of istaroxime, a new agent with lusitropic and inotropic activities that improves the cardiac contraction-relaxation cycle. The 2 doses of istaroxime (0.5 and 1.0 µg/kg/min) will be infused via i. v. for 24 hours in comparison with placebo, in treatment of Chinese and Italian patients with Acute Decompensated Heart Failure.

Read the detailed description

To assess the safety, tolerability and efficacy of two different doses of istaroxime (0.5 and 1.0 µg/kg/min) in comparison with placebo, including cardiovascular and renal tolerability, as well as changes in biological markers such as N-terminal prohormone brain natriuretic peptide (NT-proBNP) and troponin T (cTnT). The study will be conducted in 96 Chinese and Italian patients with Acute Decompensated Heart Failure. This is a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel group study. Patients were randomly assigned to one of two doses of istaroxime or placebo in a 2:1 ratio within two sequential cohorts of 60 patients each. This 31-day study includes a screening period (Days -1), a treatment period (Day 1), a post-treatment period (Days 2-4), and a follow-up period (which includes one patient visit on Day 30).

In all the Italian patients and in a subset of Chinese patients pharmacokinetics and metabolism of istaroxime shall also be studied.

03

Conditions studied

  • Acute Decompensated Heart Failure

Browse trials for

Keywords

  • safety
  • efficacy
  • istaroxime
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients who fulfill the following inclusion criteria at screening will be considered for the study:

  1. Signed ;
  2. Male or female patients 18-85 years (inclusive);
  3. Admission for a recurrent acute decompensated heart failure (ADHF) episode with dyspnea at rest or minimal exertion and need of intravenous diuretic therapy (≥40 mg iv. furosemide);
  4. Systolic blood pressure between 90 and 125 mmHg (limits included) without signs or symptoms of hypoperfusion including cardiogenic shock, cold extremities and peripheral vasoconstriction, oliguria/anuria, signs of cerebral hypo perfusion such as confusion;
  5. Left ventricular (LV) (EF) ≤ 40 % measured by 2D-Echocardiography
  6. E/Ea ratio >10
  7. BNP ≥ 350pg/mL or NT-pro-BNP ≥1400 pg/mL
  8. Adequate echocardiography window (defined as visualization of at least 13/16 segment of the left ventricle);

Exclusion criteria

Exclusion Criteria:

Any of the following criteria established at screening would render a patient ineligible for the study:

  1. Pregnant or breast-feeding women (women of child bearing potential must have the results of a negative pregnancy test recorded prior to study drug administration)
  2. Current (within 12 hours prior to screening) or planned (through the completion of study drug infusion) treatment with any iv. therapies, including vasodilators (including nitrates or nesiritide), positive inotropic agents and vasopressors
  3. Current or need of mechanical support (intra-aortic balloon pump, endotracheal intubation, mechanical ventilation, or any ventricular assist device),
  4. Ongoing treatment with oral digoxin. Patient treated with digoxin within the last week, can be randomised if the plasma concentration of digoxin is tested before randomization and its value will be less than 0.5 ng/ml.
  5. History of to the study medication or any related medication
  6. Diagnosis of cardiogenic shock within the past month;
  7. Acute coronary syndrome or stroke within the past 3 months;
  8. Coronary artery bypass graft or percutaneous coronary intervention within the past month or planned in the next month;
  9. Primary hypertrophic or restrictive cardiomyopathy or systemic illness known to be associated with infiltrative heart disease;
  10. Cor pulmonale or other causes of right-sided heart failure (HF) not related to left ventricular dysfunction;
  11. Pericardial constriction or active pericarditis;
  12. Atrial fibrillation with marked irregularities of heart rhythm;
  13. Life threatening ventricular arrhythmia or implantable cardioverter-defibrillator (ICD) shock within the past month;
  14. Cardiac resynchronization therapy (CRT), ICD, or pacemaker implantation within the past month;
  15. Valvular disease as primary cause of HF;
  16. Heart rate >120 bpm or \< 50 bpm
  17. Acute respiratory distress syndrome or ongoing sepsis;
  18. Fever >38°
  19. History of bronchial asthma or porphyria;
  20. Donation or loss of blood equal to or exceeding 500 mL, during the 8 weeks before administration of study medication;
  21. Positive testing for , and/or ;
  22. Participation in another interventional study within the past 30 days;
  23. The following laboratory exclusion criteria, verified based on results obtained within the last 24 hours of hospitalization:

    1. Serum creatinine > 3.0 mg/dl (> 265 µmol/L);
    2. (ASAT) or alanine aminotransferase (ALAT) > 3 x ,
    3. (Hb) \< 10 g/dL,
    4. count \< 100,000/µL,
    5. Serum potassium > 5.3 mmol/L or \< 3.8 mmol/L,
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    IV infusion of placebo for 24 hours

    Drug: Placebo

  • Experimental
    Istaroxime 0.5 µg/kg/min

    The istaroxime treatment dosed at 0.5 µg/kg/min via IV infusion for 24 hours

    Drug: Istaroxime

  • Experimental
    Istaroxime 1.0 µg/kg/min

    The istaroxime treatment dosed at 1.0 µg/kg/min via IV infusion for 24 hours

    Drug: Istaroxime

Interventions

  • DrugPlacebo

    IV of matching saline solution

  • IV infusion of 0.5 µg/kg/min or 1.0 µg/kg/min istaroxime

06

What researchers measure

Primary outcomes

  1. Change in E/Ea Ratio

    Change from baseline at 24 hours in the unitless ratio of E (cm/sec) to Ea (or e') (cm/sec) as measured by echocardiogram. The endpoint is the Tissue Doppler echocardiography showing measurement of mitral E/Ea ratio for assessment of diastolic dysfunction. Initially mitral E wave is measured. After that, color Tissue Doppler (tissue velocity imaging or TVI) mode is switched on to assess tissue Doppler. The cursor is placed over the medial mitral annulus and tissue Doppler tracing obtained. This allows Ea velocity to be measured. Higher values are suggestive of a worse outcome; less than 8 is normal.

    Time frame: 24 hours

Secondary outcomes

  1. Change in LVEF

    Change from baseline at 24 hours in LV ejection fraction (LVEF) by tissue Doppler

    Time frame: 24 hours

  2. Change in SVI

    Change from baseline at 24 hours in stroke volume index (SVI) by tissue Doppler

    Time frame: 24 hours

  3. Change in E/A Ratio

    Change from baseline at 24 hours in E/A ratio by tissue Doppler

    Time frame: 24 hours

  4. Change in LV End Systolic Volume

    Change from baseline in left ventricular end systolic volume (LVESV) by tissue Doppler

    Time frame: 24 hours

  5. Change in LV End Diastolic Volume

    Change from baseline in left ventricular end diastolic volume (LVEDV) by tissue Doppler

    Time frame: 24 hours

  6. Change in Dyspnea

    Measured using a visual analog scale (0 to 100). Higher scores indicate less dyspnea.

    Time frame: 24 hours

Other outcomes

  1. Change in cTnT

    Safety endpoint: Changes in troponin (cTnT)

    Time frame: 24 hours

  2. Change in eGFR

    Safety endpoint: Change from baseline in estimated glomerular filtration rate (eGFR)

    Time frame: 24 Hours

  3. Participants With Clinically or Hemodynamically Significant Episodes of Arrhythmias

    Safety endpoint: Number of participants with incidence of clinically or hemodynamically significant episodes of supraventricular or ventricular arrhythmias detected by continuous ECG dynamic monitoring

    Time frame: 24 hours

  4. PR Interval

    Safety Endpoint: The PR interval, measured in milliseconds, extends from the beginning of the P wave (the onset of atrial depolarization) until the beginning of the QRS complex (the onset of ventricular depolarization).

    Time frame: 24 Hours

  5. QRS Duration

    Safety endpoint: The quasi-random signal (QRS) duration represents the time for ventricular depolarization, normally 0.06 to 0.10 seconds.

    Time frame: 24 hours

  6. QTc Interval

    Safety Endpoint: The corrected QT interval (QTc) on an ECG represents the duration in milliseconds of the ventricular action potential, which physiologically correlates with the duration of the ventricular depolarization and repolarization.

    Time frame: 24 Hours

  7. All-Cause Mortality at Day 30

    Safety endpoint: Mortality at Day 30

    Time frame: 30 days

  8. RBC - Shift

    Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in red blood cells (RBC)

    Time frame: Day 3

  9. Hematocrit - Shift

    Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in hematocrit

    Time frame: Day 3

  10. Hemoglobin - Shift

    Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in hemoglobin

    Time frame: Day 3

  11. White Blood Cells (WBC) - Shift

    Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in WBC

    Time frame: Day 3

  12. Platelets - Shift

    Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in platelets

    Time frame: Day 3

  13. Potassium - Shift

    Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in potassium

    Time frame: Day 3

  14. Sodium - Shift

    Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in sodium

    Time frame: Day 3

  15. Calcium - Shift

    Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in calcium

    Time frame: Day 3

  16. BUN - Shift

    Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in blood urea nitrogen (BUN)

    Time frame: Day 3

  17. ALT - Shift

    Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in alanine aminotransferase (ALT)

    Time frame: Day 3

  18. AST - Shift

    Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in aspartate aminotransferase (AST)

    Time frame: Day 3

  19. Total Bilirubin - Shift

    Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in total bilirubin

    Time frame: Day 3

07

Results

Posted May 24, 2023
Limitations and caveats
The major limitation of this study regards enrollment discrepancies between the study populations and sites of the two cohorts, with Cohort 2 enrolling exclusively Asian patients. We observed that patients enrolled in this trial were younger and with a better renal function compared to other studies.

Participant flow

Participant flow — Overall Study
MilestonePlaceboIstaroxime 0.5 µg/kg/MinIstaroxime 1.0 µg/kg/Min
Started394140
Completed353933
Not completed427
Withdrew: Withdrawal by subject020
Withdrew: Adverse event105
Withdrew: Lost to follow-up300
Withdrew: Death002

Outcome measures

PrimaryChange in E/Ea Ratio

Change from baseline at 24 hours in the unitless ratio of E (cm/sec) to Ea (or e') (cm/sec) as measured by echocardiogram. The endpoint is the Tissue Doppler echocardiography showing measurement of mitral E/Ea ratio for assessment of diastolic dysfunction. Initially mitral E wave is measured. After that, color Tissue Doppler (tissue velocity imaging or TVI) mode is switched on to assess tissue Doppler. The cursor is placed over the medial mitral annulus and tissue Doppler tracing obtained. This allows Ea velocity to be measured. Higher values are suggestive of a worse outcome; less than 8 is normal.

Time frame:
24 hours
Reported as:
Least squares mean · Unitless ratio
Change in E/Ea Ratio
Unitless ratioIstaroxime 0.5 µg/kg/MinPlacebo Cohort IIstaroxime 1.0 µg/kg/MinPlacebo Cohort II
Change in E/Ea Ratio-4.55 (-6.05 to -3.04)-1.55 (-3.77 to 0.67)-3.16 (-4.09 to -2.24)-1.08 (-2.30 to 0.13)
Statistical analysis
  • Istaroxime 0.5 µg/kg/Min vs Placebo Cohort I · ANOVA · p = 0.029 (Alpha set at 0.05.) · Mean difference (final values): -3.00 · 95% CI -5.68 to -0.32Treatment term included in the model
  • Istaroxime 1.0 µg/kg/Min vs Placebo Cohort II · ANOVA · p = 0.009 (Alpha set at 0.05.) · Mean difference (final values): -2.08 · 95% CI -3.61 to -0.55Treatment term included in the model
SecondaryChange in LVEF

Change from baseline at 24 hours in LV ejection fraction (LVEF) by tissue Doppler

Time frame:
24 hours
Reported as:
Mean · % of blood leaving the heart
Change in LVEF
% of blood leaving the heartIstaroxime 0.5 µg/kg/MinPlacebo Cohort IIstaroxime 1.0 µg/kg/MinPlacebo Cohort II
Change in LVEF3.026 (1.850 to 4.203)1.263 (-0.401 to 2.927)3.818 (2.362 to 5.275)2.833 (0.861 to 4.805)
Statistical analysis
  • Istaroxime 0.5 µg/kg/Min vs Placebo Cohort I · ANOVA · p = 0.089 (Alpha set at 0.05. No adjustment for multiple comparisons) · Mean difference (final values): 1.7632 · 95% CI -0.2751 to 3.8014Treatment term included in the model
  • Istaroxime 1.0 µg/kg/Min vs Placebo Cohort II · ANOVA · p = 0.423 (Alpha set at 0.05. No adjustment for multiple comparisons) · Mean difference (final values): 0.9848 · 95% CI -1.4668 to 3.4365Treatment term included in the model
SecondaryChange in SVI

Change from baseline at 24 hours in stroke volume index (SVI) by tissue Doppler

Time frame:
24 hours
Reported as:
Least squares mean · mL/m²
Change in SVI
mL/m²Istaroxime 0.5 µg/kg/MinPlacebo Cohort IIstaroxime 1.0 µg/kg/MinPlacebo Cohort II
Change in SVI5.334 (3.371 to 7.296)1.649 (-1.126 to 4.425)5.488 (3.882 to 7.094)3.178 (1.030 to 5.327)
Statistical analysis
  • Istaroxime 0.5 µg/kg/Min vs Placebo Cohort I · ANOVA · p = 0.034 (Alpha set at 0.05. No adjustment for multiple comparisons) · Mean difference (final values): 3.684 · 95% CI 0.285 to 7.083Treatment term is in the model.
  • Istaroxime 1.0 µg/kg/Min vs Placebo Cohort II · ANOVA · p = 0.090 (Alpha set at 0.05. No adjustment for multiple comparisons) · Mean difference (final values): 2.310 · 95% CI -0.373 to 4.992Treatment term is in the model
SecondaryChange in E/A Ratio

Change from baseline at 24 hours in E/A ratio by tissue Doppler

Time frame:
24 hours
Reported as:
Least squares mean · Unitless ratio
Change in E/A Ratio
Unitless ratioIstaroxime 0.5 µg/kg/MinPlacebo Cohort IIstaroxime 1.0 µg/kg/MinPlacebo Cohort II
Change in E/A Ratio-0.643 (-1.091 to -0.197)0.133 (-0.463 to 0.729)-0.654 (-1.093 to -0.216)0.175 (-0.419 to 0.769)
Statistical analysis
  • Istaroxime 0.5 µg/kg/Min vs Placebo Cohort I · ANOVA · p = 0.042 (Alpha set at 0.05. No adjustment for multiple comparisons) · Mean difference (final values): -0.777 · 95% CI -1.522 to -0.032Treatment term is included in the model
  • Istaroxime 1.0 µg/kg/Min vs Placebo Cohort II · ANOVA · p = 0.029 (Alpha set at 0.05. No adjustment for multiple comparisons) · Mean difference (final values): -0.829 · 95% CI -1.568 to -0.091Treatment term is in the model
SecondaryChange in LV End Systolic Volume

Change from baseline in left ventricular end systolic volume (LVESV) by tissue Doppler

Time frame:
24 hours
Reported as:
Least squares mean · mL
Change in LV End Systolic Volume
mLIstaroxime 0.5 µg/kg/MinPlacebo Cohort IIstaroxime 1.0 µg/kg/MinPlacebo Cohort II
Change in LV End Systolic Volume-7.105 (-10.933 to -3.277)-1.736 (-7.150 to 3.677)-11.39 (-17.438 to -5.350)-11.83 (-20.017 to -3.649)
Statistical analysis
  • Istaroxime 0.5 µg/kg/Min vs Placebo Cohort I · ANOVA · p = 0.110 (Alpha set at 0.05. No adjustment for multiple comparisons) · Mean difference (final values): -5.368 · 95% CI -11.999 to 1.262Treatment term is in the model
  • Istaroxime 1.0 µg/kg/Min vs Placebo Cohort II · ANOVA · p = 0.931 (Alpha set at 0.05. No adjustment for multiple comparisons) · Mean difference (final values): 0.439 · 95% CI -9.735 to 10.614Treatment term is in the model
SecondaryChange in LV End Diastolic Volume

Change from baseline in left ventricular end diastolic volume (LVEDV) by tissue Doppler

Time frame:
24 hours
Reported as:
Least squares mean · mL
Change in LV End Diastolic Volume
mLIstaroxime 0.5 µg/kg/MinPlacebo Cohort IIstaroxime 1.0 µg/kg/MinPlacebo Cohort II
Change in LV End Diastolic Volume-0.710 (-4.243 to 2.822)0.947 (-4.049 to 5.944)-3.666 (-9.507 to 2.173)-7.611 (-15.518 to 0.296)
Statistical analysis
  • Istaroxime 0.5 µg/kg/Min vs Placebo Cohort I · ANOVA · p = 0.589 (Alpha set at 0.05. No adjustment for multiple comparisons) · Mean difference (final values): -1.657 · 95% CI -7.777 to 4.461Treatment term in the model
  • Istaroxime 1.0 µg/kg/Min vs Placebo Cohort II · ANOVA · p = 0.424 (Alpha set at 0.05. No adjustment for multiple comparisons) · Mean difference (final values): 3.944 · 95% CI -5.886 to 13.774Treatment term is in the model.
SecondaryChange in Dyspnea

Measured using a visual analog scale (0 to 100). Higher scores indicate less dyspnea.

Time frame:
24 hours
Reported as:
Mean · Score on a scale (Visual Analog Scale)
Change in Dyspnea
Score on a scale (Visual Analog Scale)PlaceboIstaroxime 0.5 µg/kg/MinIstaroxime 1.0 µg/kg/Min
Change in Dyspnea9.75 ± 11.809.14 ± 10.0812.09 ± 14.79
Statistical analysis
  • Placebo vs Istaroxime 0.5 µg/kg/Min · Mixed Models Analysis · p = 0.987 (Unadjusted alpha of 0.05 is the threshold for statistical significance.) · Mean difference (final values): -0.041 · 95% CI -5.216 to 5.133Kenward-Roger adjustment used for the degrees of freedom.
  • Placebo vs Istaroxime 1.0 µg/kg/Min · Mixed Models Analysis · p = 0.251 (Unadjusted alpha of 0.05 is the threshold for statistical significance.) · Mean difference (final values): 3.015 · 95% CI -2.168 to 8.198Kenward-Roger adjustment used for the degrees of freedom.
Other pre-specifiedChange in cTnT

Safety endpoint: Changes in troponin (cTnT)

Time frame:
24 hours
Reported as:
Mean · ng/L
Change in cTnT
ng/LPlaceboIstaroxime 0.5 µg/kg/MinIstaroxime 1.0 µg/kg/Min
Change in cTnT0.23 ± 10.830.51 ± 7.58-4.06 ± 49.97
Other pre-specifiedChange in eGFR

Safety endpoint: Change from baseline in estimated glomerular filtration rate (eGFR)

Time frame:
24 Hours
Reported as:
Mean · ml/min/1.73·m²
Change in eGFR
ml/min/1.73·m²PlaceboIstaroxime 0.5 µg/kg/MinIstaroxime 1.0 µg/kg/Min
Change in eGFR-0.60 ± 14.715.19 ± 16.257.65 ± 13.22
Other pre-specifiedParticipants With Clinically or Hemodynamically Significant Episodes of Arrhythmias

Safety endpoint: Number of participants with incidence of clinically or hemodynamically significant episodes of supraventricular or ventricular arrhythmias detected by continuous ECG dynamic monitoring

Time frame:
24 hours
Reported as:
Count of participants · Participants
Participants With Clinically or Hemodynamically Significant Episodes of Arrhythmias
ParticipantsPlaceboIstaroxime 0.5 µg/kg/MinIstaroxime 1.0 µg/kg/Min
Participants With Clinically or Hemodynamically Significant Episodes of Arrhythmias614
Other pre-specifiedPR Interval

Safety Endpoint: The PR interval, measured in milliseconds, extends from the beginning of the P wave (the onset of atrial depolarization) until the beginning of the QRS complex (the onset of ventricular depolarization).

Time frame:
24 Hours
Reported as:
Mean · msec
PR Interval
msecPlaceboIstaroxime 0.5 µg/kg/MinIstaroxime 1.0 µg/kg/Min
PR Interval184.0 ± 31.27179.2 ± 28.11169.41 ± 32.72
Other pre-specifiedQRS Duration

Safety endpoint: The quasi-random signal (QRS) duration represents the time for ventricular depolarization, normally 0.06 to 0.10 seconds.

Time frame:
24 hours
Reported as:
Mean · msec
QRS Duration
msecPlaceboIstaroxime 0.5 µg/kg/MinIstaroxime 1.0 µg/kg/Min
QRS Duration125.2 ± 37.11132.5 ± 31.59127.6 ± 26.65
Other pre-specifiedQTc Interval

Safety Endpoint: The corrected QT interval (QTc) on an ECG represents the duration in milliseconds of the ventricular action potential, which physiologically correlates with the duration of the ventricular depolarization and repolarization.

Time frame:
24 Hours
Reported as:
Mean · msec
QTc Interval
msecPlaceboIstaroxime 0.5 µg/kg/MinIstaroxime 1.0 µg/kg/Min
QTc Interval472.8 ± 41.90480.8 ± 55.72486.9 ± 40.18
Other pre-specifiedAll-Cause Mortality at Day 30

Safety endpoint: Mortality at Day 30

Time frame:
30 days
Reported as:
Count of participants · Participants
All-Cause Mortality at Day 30
ParticipantsPlaceboIstaroxime 0.5 µg/kg/MinIstaroxime 1.0 µg/kg/Min
All-Cause Mortality at Day 30002
Other pre-specifiedRBC - Shift

Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in red blood cells (RBC)

Time frame:
Day 3
Reported as:
Count of participants · Participants
RBC - Shift
ParticipantsPlaceboIstaroxime 0.5 µg/kg/MinIstaroxime 1.0 µg/kg/Min
Normal to Normal221721
Normal to Abnormal534
Abnormal to Normal234
Abnormal to Abnormal8167
Missing224
Other pre-specifiedHematocrit - Shift

Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in hematocrit

Time frame:
Day 3
Reported as:
Count of participants · Participants
Hematocrit - Shift
ParticipantsPlaceboIstaroxime 0.5 µg/kg/MinIstaroxime 1.0 µg/kg/Min
Normal to Normal211517
Normal to Abnormal735
Abnormal to Normal376
Abnormal to Abnormal6148
Missing224
Other pre-specifiedHemoglobin - Shift

Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in hemoglobin

Time frame:
Day 3
Reported as:
Count of participants · Participants
Hemoglobin - Shift
ParticipantsPlaceboIstaroxime 0.5 µg/kg/MinIstaroxime 1.0 µg/kg/Min
Normal to Normal231323
Normal to Abnormal532
Abnormal to Normal175
Abnormal to Abnormal8166
Missing224
Other pre-specifiedWhite Blood Cells (WBC) - Shift

Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in WBC

Time frame:
Day 3
Reported as:
Count of participants · Participants
White Blood Cells (WBC) - Shift
ParticipantsPlaceboIstaroxime 0.5 µg/kg/MinIstaroxime 1.0 µg/kg/Min
Normal to Normal353025
Normal to Abnormal266
Abnormal to Normal012
Abnormal to Abnormal023
Missing224
Other pre-specifiedPlatelets - Shift

Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in platelets

Time frame:
Day 3
Reported as:
Count of participants · Participants
Platelets - Shift
ParticipantsPlaceboIstaroxime 0.5 µg/kg/MinIstaroxime 1.0 µg/kg/Min
Normal to Normal263231
Normal to Abnormal324
Abnormal to Normal410
Abnormal to Abnormal431
Missing234
Other pre-specifiedPotassium - Shift

Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in potassium

Time frame:
Day 3
Reported as:
Count of participants · Participants
Potassium - Shift
ParticipantsPlaceboIstaroxime 0.5 µg/kg/MinIstaroxime 1.0 µg/kg/Min
Normal to Normal374034
Normal to Abnormal102
Abnormal to Normal000
Abnormal to Abnormal000
Missing114
Other pre-specifiedSodium - Shift

Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in sodium

Time frame:
Day 3
Reported as:
Count of participants · Participants
Sodium - Shift
ParticipantsPlaceboIstaroxime 0.5 µg/kg/MinIstaroxime 1.0 µg/kg/Min
Normal to Normal232119
Normal to Abnormal9128
Abnormal to Normal421
Abnormal to Abnormal258
Missing114
Other pre-specifiedCalcium - Shift

Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in calcium

Time frame:
Day 3
Reported as:
Count of participants · Participants
Calcium - Shift
ParticipantsPlaceboIstaroxime 0.5 µg/kg/MinIstaroxime 1.0 µg/kg/Min
Normal to Normal242620
Normal to Abnormal421
Abnormal to Normal329
Abnormal to Abnormal314
Missing5106
Other pre-specifiedBUN - Shift

Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in blood urea nitrogen (BUN)

Time frame:
Day 3
Reported as:
Count of participants · Participants
BUN - Shift
ParticipantsPlaceboIstaroxime 0.5 µg/kg/MinIstaroxime 1.0 µg/kg/Min
Normal to Normal111314
Normal to Abnormal746
Abnormal to Normal328
Abnormal to Abnormal14167
Missing465
Other pre-specifiedALT - Shift

Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in alanine aminotransferase (ALT)

Time frame:
Day 3
Reported as:
Count of participants · Participants
ALT - Shift
ParticipantsPlaceboIstaroxime 0.5 µg/kg/MinIstaroxime 1.0 µg/kg/Min
Normal to Normal293129
Normal to Abnormal112
Abnormal to Normal210
Abnormal to Abnormal455
Missing334
Other pre-specifiedAST - Shift

Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in aspartate aminotransferase (AST)

Time frame:
Day 3
Reported as:
Count of participants · Participants
AST - Shift
ParticipantsPlaceboIstaroxime 0.5 µg/kg/MinIstaroxime 1.0 µg/kg/Min
Normal to Normal282824
Normal to Abnormal145
Abnormal to Normal314
Abnormal to Abnormal443
Missing344
Other pre-specifiedTotal Bilirubin - Shift

Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in total bilirubin

Time frame:
Day 3
Reported as:
Count of participants · Participants
Total Bilirubin - Shift
ParticipantsPlaceboIstaroxime 0.5 µg/kg/MinIstaroxime 1.0 µg/kg/Min
Normal to Normal92113
Normal to Abnormal322
Abnormal to Normal936
Abnormal to Abnormal131115
Missing544

Adverse events

Collected over Enrollment to 30 days after enrollment. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/39 (0%)2/39 (5.1%)23/39 (59%)
Istaroxime 0.5 µg/kg/Min0/41 (0%)2/41 (4.9%)31/41 (75.6%)
Istaroxime 1.0 µg/kg/Min2/40 (5%)6/40 (15%)33/40 (82.5%)
Most frequent serious events
Most frequent serious events
EventPlaceboIstaroxime 0.5 µg/kg/MinIstaroxime 1.0 µg/kg/Min
Cardiac failureCardiac disorders1/392/412/40
Transient ischaemic attackNervous system disorders1/390/410/40
HyperventilationRespiratory, thoracic and mediastinal disorders1/390/410/40
HypotensionVascular disorders1/390/410/40
Cardiac failure congestiveCardiac disorders0/390/411/40
Cardiogenic shockCardiac disorders0/390/411/40
Cardiac deathGeneral disorders0/390/411/40
Renal embolismRenal and urinary disorders0/390/411/40
Most frequent other events
Showing 10 of 36
Most frequent other events
EventPlaceboIstaroxime 0.5 µg/kg/MinIstaroxime 1.0 µg/kg/Min
Infusion site painGeneral disorders0/3917/4112/40
VomitingGastrointestinal disorders1/391/4110/40
NauseaGastrointestinal disorders0/393/419/40
HypotensionVascular disorders6/393/411/40
DizzinessNervous system disorders0/391/415/40
PhlebitisVascular disorders0/395/412/40
Upper respiratory tract infectionInfections and infestations0/393/414/40
Atrial fibrillationCardiac disorders0/394/410/40
Blood bilirubin increasedInvestigations2/394/410/40
Cardiac failureCardiac disorders3/390/410/40

Baseline characteristics

Intent-to-Treat

Age, Continuous
Age, Continuous(years)PlaceboIstaroxime 0.5 µg/kg/MinIstaroxime 1.0 µg/kg/MinTotal
Mean56.67 ± 16.2159.73 ± 15.5352.23 ± 13.0256.24 ± 14.98
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboIstaroxime 0.5 µg/kg/MinIstaroxime 1.0 µg/kg/MinTotal
Female57618
Male343434102
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboIstaroxime 0.5 µg/kg/MinIstaroxime 1.0 µg/kg/MinTotal
American Indian or Alaska Native0000
Asian32244096
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White717024
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)PlaceboIstaroxime 0.5 µg/kg/MinIstaroxime 1.0 µg/kg/MinTotal
China32244096
Italy717024
E/Ea Ratio
E/Ea Ratio(Unitless ratio)PlaceboIstaroxime 0.5 µg/kg/MinIstaroxime 1.0 µg/kg/MinTotal
Mean17.0 ± 5.3320.4 ± 7.8715.1 ± 5.4817.5 ± 6.36
Left ventricular ejection fraction (LVEF)
Left ventricular ejection fraction (LVEF)(% of blood in heart pumped)PlaceboIstaroxime 0.5 µg/kg/MinIstaroxime 1.0 µg/kg/MinTotal
Mean26.2 ± 7.427.4 ± 6.728.7 ± 7.227.4 ± 7.1
Stroke Volume Index
Stroke Volume Index(ml/m²)PlaceboIstaroxime 0.5 µg/kg/MinIstaroxime 1.0 µg/kg/MinTotal
Mean21.6 ± 7.7325.9 ± 7.1017.1 ± 5.6921.6 ± 6.89
Dyspnea
Dyspnea(Scores on a scale)PlaceboIstaroxime 0.5 µg/kg/MinIstaroxime 1.0 µg/kg/MinTotal
Mean70.8 ± 21.3273.6 ± 19.4971.5 ± 20.9572.0 ± 20.59

2 further baseline measures are reported on the registry.

08

Study locations

11 sites
  • Lanzhou University No.2 Hospital
    Lanzhou, Gansu, China
  • The First Hospital of Lanzhou University
    Lanzhou, Gansu, China
  • Renmin Hospital of Wuhan University
    Wuhan, Hubei, China
  • Jiangsu Province People's Hospital
    Nanjing, Jiangsu, China
  • The General Hospital Of Shenyang Military Region
    Shenyang, Liaoning, China
  • The First Affiliated Hospital Of Xi'an Jiaotong University
    Xi'an, Shaanxi, China
  • Fuwai Hospital Chinese Academy of Medical Sciences
    Beijing, 100037, China
  • Beijing Chao Yang Hospital
    Beijing, China
  • The 307th Hospital of Chinese People's Liberation Army
    Beijing, China
  • University and Civil Hospital of Brescia
    Brescia, Italy
  • University of Milano-Bicocca
    Milan, Italy
09

References and documents

Publications

  • Carubelli V, Zhang Y, Metra M, Lombardi C, Felker GM, Filippatos G, O'Connor CM, Teerlink JR, Simmons P, Segal R, Malfatto G, La Rovere MT, Li D, Han X, Yuan Z, Yao Y, Li B, Lau LF, Bianchi G, Zhang J; Istaroxime ADHF Trial Group. Treatment with 24 hour istaroxime infusion in patients hospitalised for acute heart failure: a randomised, placebo-controlled trial. Eur J Heart Fail. 2020 Sep;22(9):1684-1693. doi: 10.1002/ejhf.1743. Epub 2020 Jan 23. PubMed 31975496 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2015, a primary completion of Aug 2018 and a completion of Feb 2019. It does not say whether these dates are actual or estimated.

Results were first posted in May 2023, 4 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2015
First posted
Dec 1, 2015
Start
Dec 2015
Primary completionActual
Aug 14, 2018
CompletionActual
Feb 6, 2019
Results first posted
May 24, 2023
Last update
May 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02617446
Lead sponsor
Windtree Therapeutics
Responsible party
Sponsor
First posted
Dec 1, 2015
Start date
Dec 2015
Primary completion
Aug 14, 2018
Completion
Feb 6, 2019
Results posted
May 24, 2023
Last update
May 24, 2023

Study contacts

Giuseppe Bianchi, MD
principal investigator · Windtree Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Istaroxime

Start the discussion